Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016
Published Aug 31, 2016
71 pages — Published Aug 31, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016, provides in depth analysis on Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted pipeline therapeutics.

The report provides comprehensive information on the Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)
- The report reviews Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to g

  
Source:
Document ID
GMDHC0503TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Overview61
Therapeutics Development74
  Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Products under Development by Stage of Development71
  Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Products under Development by Therapy Area81
  Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Products under Development by Indication92
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Pipeline Products Glance112
  Late Stage Products111
  Early Stage Products121
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Products under Development by Companies134
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Therapeutics Assessment175
  Assessment by Monotherapy/Combination Products171
  Assessment by Mechanism of Action181
  Assessment by Route of Administration192
  Assessment by Molecule Type211
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Companies Involved in Therapeutics Development223
  Karyopharm Therapeutics, Inc.222
  Stemline Therapeutics, Inc.241
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Drug Profiles2526
  KPT-251 Drug Profile251
  KPT-276 Drug Profile261
  KPT-350 Drug Profile272
  KPT-8602 Drug Profile292
  selinexor Drug Profile3117
  SL-801 Drug Profile482
  verdinexor Drug Profile501
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Dormant Projects513
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Discontinued Products541
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Featured News &Press Releases5515
  Jul 27, 2016: Karyopharm to Present Updated Phase 2 Clinical Data from SIGN Study at European Society of Medical Oncology 2016 Annual Meeting551
  Jul 27, 2016: Karyopharms Selinexor First-in-Human Phase 1 Clinical Trial Data Published in Journal of Clinical Oncology561
  Jun 16, 2016: Karyopharm Outlines Key Selinexor Clinical Development Achievements571
  Jun 10, 2016: Karyopharm Presents Preliminary STOMP Phase 1b Clinical Data at 2016 European Hematology Association Annual Meeting581
  Jun 10, 2016: Karyopharm Therapeutics Presents data on KPT-8602 at 2016 European Hematology Association Annual Meeting591
  Jun 06, 2016: Moffitt researchers present phase 1 study results of selinexor combination therapy; multiple myeloma601
  May 19, 2016: Karyopharm to Present Preliminary STOMP Phase 1B Clinical Data at 2016 European Hematology Association Annual Meeting601
  May 18, 2016: Karyopharm to Present Selinexor Clinical Data at the American Society of Clinical Oncology Annual Meeting612
  May 03, 2016: Stemline Therapeutics Clears First Cohort of Patients in Ongoing SL-801 Phase 1 Trial631
  Apr 20, 2016: Karyopharm Presents Data Demonstrating the Potential of Nuclear Export Protein Exportin 1 (XPO1) Inhibition in the Treatment of Traumatic Brain Injury631
  Mar 31, 2016: Karyopharm Receives NIAID Grant to Advance Development of KPT-350 for the Treatment of Lupus641
  Mar 16, 2016: Karyopharm to Present Data on Oncology drug Selinexor (KPT-330) at the 2016 American Association for Cancer Research Annual Meeting652
  Mar 16, 2016: Karyopharm to Present Data on Oncology drug KPT-8602 at the 2016 American Association for Cancer Research Annual Meeting671
  Mar 04, 2016: Karyopharm s Selinexor First-in-Human Phase 1 Clinical Trial Data Published in Journal of Clinical Oncology681
  Jan 19, 2016: Karyopharm Initiates Second Generation SINE Compound Clinical Trial in Multiple Myeloma691
Appendix702
  Methodology701
  Coverage701
  Secondary Research701
  Primary Research701
  Expert Panel Validation701
  Contact Us701
  Disclaimer711

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016" Aug 31, 2016. Alacra Store. May 11, 2025. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Exportin-1-Chromosome-Region-Maintenance-1-Protein-Homolog-or-XPO1-Pipeline-Review-H2-2016-2088-16523>
  
APA:
Global Markets Direct - Market Research. (2016). Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016 Aug 31, 2016. New York, NY: Alacra Store. Retrieved May 11, 2025 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Exportin-1-Chromosome-Region-Maintenance-1-Protein-Homolog-or-XPO1-Pipeline-Review-H2-2016-2088-16523>
  
US$ 3,500.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.